CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 13 No. 3
 

Genes Linked to Early Onset, Distal Location of Hereditary Colon Cancer

March 1, 1999

Researchers have identified a mechanism that may explain where colorectal tumors arise and at what age the tumors develop in people with hereditary nonpolyposis colorectal cancer (HNPCC). The results of the study, conducted at Ohio State’s Comprehensive Cancer Center, help clarify why some people with the same HNPCC-related genetic mutation develop colorectal tumors at 30 years of age while others develop tumors at age 60. They also help explain why tumors in some patients develop in the distal area of the large intestine rather than in regions closer to the large intestine’s junction with the small intestine, which is more typical.

Genetic Capacity to Detoxify Carcinogens

The genes identified by the researchers are all involved in the detoxification of cancer-causing chemicals in cells. “Our findings suggest that even in individuals with a strong genetic predisposition to colorectal cancer, exposure to carcinogens and an individual’s genetic capacity to detoxify them, may play a role in the development of tumors,” said Paivi Peltomaki, MD, PhD, associate professor in the Human Cancer Genetics Program at Ohio State’s Comprehensive Cancer Center and leader of the study.

The findings also imply that measures found to help prevent colon cancer may help delay its onset in people genetically predisposed to the disease. These measures include eating a diet high in fruits, vegetables, and whole grains; avoiding foods that are high in fat and low in fiber; and getting at least 30 minutes of physical activity on most days.

The study appeared in the December 1999 issue of Gastroenterology. It involved 76 individuals in Finland with HNPCC who had colorectal tumors. These individuals all had the HNPCC-related mutation in the MLH1 gene, one of five genes linked to HNPCC.

The average age of cancer diagnosis in the group was about 42 years; individually, however, the age at diagnosis ranged from 26 to 55 years. Generally, average age of onset for colorectal cancer is 70 to 75 years.

Proximal tumors in the group were twice as common as distal tumors. This 2:1 ratio of proximal to distal tumors is typical of HNPCC, but why most people develop proximal tumors and some develop distal tumors has been unknown.

NAT1, GSTM1, and GSTT1

To explore this variation in age of onset and tumor location, the researchers looked at three genes that produce enzymes for detoxifying cancer-causing chemicals: the gene for N-acetyltransferase 1 (NAT1) and two forms of the glutathione S-transferase (GST) gene, GSTM1 and GSTT1, respectively. Specifically, the researchers looked for the presence or absence of GSTM1 and GSTT1.

The NAT1 gene is responsible for processing highly carcinogenic aromatic amines frequently found in the environment, in the diet, and in cigarette smoke. The GST enzymes detoxify a variety of carcinogens and toxic drugs. The researchers found that patients with one form of the NAT1 gene, known as NAT1-l0, who were missing the GSTM1 and GSTT1 genes tended to develop colorectal tumors at a younger age. When they looked at tumor location, they found that nearly half of patients with the NAT1-10 gene had distal tumors, which is significantly higher than the typical population with HNPCC.

People who had the GSTT1 gene also tended to have more tumors located in the distal colon than is usual. There was no correlation between tumor location and the presence or absence of the GSTM1 gene. Overall, said Dr. Peltomaki, “the presence of the NAT1-10 gene in individuals was associated with earlier tumor development and with distal location of the tumor.”

Larger Study Planned

Dr. Peltomaki and her colleagues are working to verify their findings in a larger study, and they are looking for other genes that might also influence age of onset and tumor location. Hereditary nonpolyposis colorectal cancer is also associated with an increased risk of cancer of the uterus, stomach, small intestine, pancreas, and kidney. The researchers also hope to learn why some people develop these “extracolonic” tumors and others do not.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

A 48-Year-Old Woman With Irregular Vaginal Bleeding
Brian Morse, MD1 , June 10, 2013

A 48-year-old female presents with complaints of irregular vaginal bleeding and postcoital bleeding. Images from a PET/CT and pelvis MRI reveal characteristic findings. What is your diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
  • ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
  • Physical Activity Across the Cancer Continuum
  • Exercise After Cancer Diagnosis: Time to Get Moving
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • ASCO: No Benefit From Avastin in Newly Diagnosed Glioblastoma
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy